Get the Stockscreener App
4.82
1.26%
0.06
After Hours:
5.00
0.18
+3.73%
Cellectar Biosciences Inc stock is traded at $4.82, with a volume of 321.72K.
It is up +1.26% in the last 24 hours and down -5.30% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$4.76
Open:
$4.76
24h Volume:
321.72K
Relative Volume:
0.03
Market Cap:
$15.39M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-1.4831
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+9.30%
1M Performance:
-5.30%
6M Performance:
+1,577%
1Y Performance:
+119.09%
1-Day Range:
$4.7201
$5.2953
1-Week Range:
$4.22
$5.2953
52-Week Range:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.82 | 15.19M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
How sentiment analysis helps forecast Cellectar Biosciences Inc.Trade Signal Summary & Safe Investment Capital Preservation Plans - Newser
Short interest data insights for Cellectar Biosciences Inc.Options Play & Advanced Swing Trade Entry Plans - Newser
Cellectar Biosciences Inc. stock chart pattern explainedIPO Watch & Risk Controlled Swing Alerts - Newser
Cellectar Biosciences shares rise 3.74% intraday after announcing oral presentation at AACR Special Conference on Pediatric Cancer. - AInvest
Cellectar Cuts Q2 Losses and Expenses - AOL.com
What’s next for Cellectar Biosciences Inc. stock priceMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Using Ichimoku Cloud for Cellectar Biosciences Inc. technicals2025 Volume Leaders & Weekly Momentum Picks - Newser
Cellectar Biosciences Announces AACR Oral Presentation for Pediatric Cancer Treatment - AInvest
Cellectar Biosciences to Present Data in Oral Session and - GlobeNewswire
Breaking Pediatric Brain Cancer Treatment: Cellectar's Iopofosine I 131 Data Selected for Major AACR Presentation - Stock Titan
Key metrics from Cellectar Biosciences Inc.’s quarterly dataEarnings Growth Report & High Return Stock Watch Alerts - Newser
Institutional scanner results for Cellectar Biosciences Inc.Quarterly Profit Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Technical analysis overview for Cellectar Biosciences Inc. stock - Newser
Visualizing Cellectar Biosciences Inc. stock with heatmapsBull Run & Verified Stock Trade Ideas - Newser
Using AI based signals to follow Cellectar Biosciences Inc.Weekly Trade Recap & Risk Controlled Swing Trade Alerts - Newser
What high frequency data says about Cellectar Biosciences Inc.Quarterly Earnings Summary & Capital Efficient Trading Techniques - Newser
How to manage a losing position in Cellectar Biosciences Inc.Breakout Watch & Weekly High Return Stock Forecasts - Newser
Does Cellectar Biosciences Inc. show high probability of reboundJuly 2025 Short Interest & AI Enhanced Trade Execution Alerts - Newser
Multi factor analysis applied to Cellectar Biosciences Inc.July 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
Is Cellectar Biosciences Inc. stock influenced by commodity pricesQuarterly Profit Report & Community Verified Trade Signals - sundaytimes.kr
How moving averages guide Cellectar Biosciences Inc. tradingTrade Signal Summary & Safe Investment Capital Preservation Plans - Newser
Applying sector rotation models to Cellectar Biosciences Inc.Market Growth Summary & Stock Portfolio Risk Management - Newser
What recovery options are there for Cellectar Biosciences Inc.Market Movers & Accurate Buy Signal Notifications - Newser
Short Interest Drops in Cellectar Biosciences Inc. After Rally2025 Sector Review & Safe Entry Momentum Tips - newsyoung.net
Will Cellectar Biosciences Inc. see short term momentumEarnings Recap Report & Low Risk High Win Rate Stock Picks - Newser
Will Cellectar Biosciences Inc. outperform during market ralliesMarket Weekly Review & Risk Controlled Swing Alerts - theviewers.co.kr
Is Cellectar Biosciences Inc. trending in predictive chart modelsMarket Risk Summary & Entry Point Strategy Guides - Newser
XTX Topco Ltd Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Earnings Chart Overlay Points to Cellectar Biosciences Inc. UpsideQuarterly Portfolio Review & Weekly Consistent Profit Watchlists - 선데이타임즈
How high can Cellectar Biosciences Inc. stock go2025 Technical Patterns & Risk Managed Investment Signals - Newser
Advanced analytics toolkit walkthrough for Cellectar Biosciences Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN
Support Zone Holds Steady for Cellectar Biosciences Inc. After Dip2025 Winners & Losers & Daily Entry Point Trade Alerts - 선데이타임즈
Oppenheimer Maintains Hold Rating on Cellectar Biosciences with $18.00 Average Price Target - AInvest
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2025 Earnings Call Transcript - MSN
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus - MSN
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):